Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration.
about
Ocular Complications of Diabetes and Therapeutic ApproachesNanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug deliveryAAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularizationAnti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future.Molecular mechanisms of subretinal fibrosis in age-related macular degeneration.Etv2 and fli1b function together as key regulators of vasculogenesis and angiogenesis.Correlation of in vivo and in vitro methods in measuring choroidal vascularization volumes using a subretinal injection induced choroidal neovascularization model.Nanoengineering of therapeutics for retinal vascular disease.Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment.Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1.Microvascular targets for anti-fibrotic therapeuticsImmunology of age-related macular degenerationStem Cell Therapy for Corneal Regeneration Medicine and Contemporary Nanomedicine for Corneal Disorders.Cyclic RGD peptides target human trabecular meshwork cells while ameliorating connective tissue growth factor-induced fibrosis.Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.Gene delivery nanoparticles to modulate angiogenesis.Long-Term PEDF Release in Rat Iris and Retinal Epithelial Cells after Sleeping Beauty Transposon-Mediated Gene Delivery.Human Vascular Endothelial Growth Factor A Expression Induces the Mouse Model of Neovascular Age-Related Macular Degeneration
P2860
Q26749412-2134DB9F-A68F-4EBF-9DAC-7DBEC930F6F9Q27007119-CAE6939F-01DC-45AC-8F2B-981130AB188AQ27318539-9ECAD956-2E1A-4F83-955B-1AB9224182B2Q34554380-1FD3E5FC-AA50-4B2C-A0FF-2A471B37AF10Q35577823-C9936BB9-F7E3-4F1E-85EC-D2735D16AA86Q35594958-D3CC0600-6094-47D4-B797-BAEF21C4DFACQ35645359-74548CCA-CFD0-4337-80D2-606102B6CCA2Q35645705-4D33E6D8-97B3-45E6-9E0A-D568354B37C1Q36290649-C46F2AD1-7353-4895-9463-59D42F4F99A7Q36942442-A60AD7EE-A33B-43BF-861F-FB535780071DQ37358577-087AB57D-0D4B-41A6-B8D2-5790E0D7698FQ37614752-B3F697F5-F5BB-4E97-A51E-30303BE3B0D8Q38288519-9D17FEC0-177C-40F2-9AEA-461A887E2401Q38786663-5C18BADD-172F-4503-979E-D092173818E6Q38829320-84E0B4CB-030F-4BBE-B5E3-7B632EBD2E38Q39027588-3AC5925A-6B3B-4312-89D9-F3406724FD76Q46666393-BFB50BE6-341B-4638-B237-183E83FB52C7Q58779270-7E9E15B1-6A15-4086-B0C8-46A1F0B77F75
P2860
Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Targeted intraceptor nanoparti ...... d murine macular degeneration.
@ast
Targeted intraceptor nanoparti ...... d murine macular degeneration.
@en
type
label
Targeted intraceptor nanoparti ...... d murine macular degeneration.
@ast
Targeted intraceptor nanoparti ...... d murine macular degeneration.
@en
prefLabel
Targeted intraceptor nanoparti ...... d murine macular degeneration.
@ast
Targeted intraceptor nanoparti ...... d murine macular degeneration.
@en
P2093
P2860
P50
P356
P1433
P1476
Targeted intraceptor nanoparti ...... nd murine macular degeneration
@en
P2093
Balamurali K Ambati
Bonnie Archer
Brian C Stagg
Christina Mamalis
Guangping Gao
Hironori Uehara
Jayakrishna Ambati
Judit Baffi
Kristen Zygmunt
Kyle Jackman
P2860
P304
P356
10.1021/NN305958Y
P407
P577
2013-03-20T00:00:00Z